Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.

Kuhn C, Weiner HL.

Immunotherapy. 2016 Jul;8(8):889-906. doi: 10.2217/imt-2016-0049. Epub 2016 May 10. Review.

2.

Immunotherapies currently in development for the treatment of type 1 diabetes.

Davis IC, Randell J, Davis SN.

Expert Opin Investig Drugs. 2015;24(10):1331-41. doi: 10.1517/13543784.2015.1075973. Review.

PMID:
26364507
3.

Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.

Simmons K, Michels AW.

Rheum Dis Clin North Am. 2014 Nov;40(4):797-811. doi: 10.1016/j.rdc.2014.07.008. Epub 2014 Sep 2. Review.

4.

Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.

Vudattu NK, Herold KC.

Expert Opin Biol Ther. 2014 Mar;14(3):377-85. doi: 10.1517/14712598.2014.881797. Review.

PMID:
24517093
5.

Prospects for therapeutic tolerance in humans.

Baker KF, Isaacs JD.

Curr Opin Rheumatol. 2014 Mar;26(2):219-27. doi: 10.1097/BOR.0000000000000029. Review.

6.

Prevention versus intervention of type 1 diabetes.

Brooks-Worrell B, Palmer JP.

Clin Immunol. 2013 Dec;149(3):332-8. doi: 10.1016/j.clim.2013.05.018. Epub 2013 Jun 10. Review.

PMID:
23803322
7.

Anti-CD3 clinical trials in type 1 diabetes mellitus.

Daifotis AG, Koenig S, Chatenoud L, Herold KC.

Clin Immunol. 2013 Dec;149(3):268-78. doi: 10.1016/j.clim.2013.05.001. Epub 2013 May 11. Review.

PMID:
23726024

Supplemental Content

Loading ...
Support Center